A Conditionally Activated Cytosol-Penetrating Antibody for TME-Dependent Intracellular Cargo Delivery

Author:

Dombrowsky Carolin Sophie1,Happel Dominic1ORCID,Habermann Jan1,Hofmann Sarah1,Otmi Sasi2,Cohen Benny2,Kolmar Harald13ORCID

Affiliation:

1. Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Strasse 4, D-64287 Darmstadt, Germany

2. Inter-Lab, a Subsidiary of Merck KGaA, South Industrial Area, Yavne 8122004, Israel

3. Centre for Synthetic Biology, Technical University of Darmstadt, D-64287 Darmstadt, Germany

Abstract

Currently, therapeutic and diagnostic applications of antibodies are primarily limited to cell surface-exposed and extracellular proteins. However, research has been conducted on cell-penetrating peptides (CPP), as well as cytosol-penetrating antibodies, to overcome these limitations. In this context, a heparin sulfate proteoglycan (HSPG)-binding antibody was serendipitously discovered, which eventually localizes to the cytosol of target cells. Functional characterization revealed that the tested antibody has beneficial cytosol-penetrating capabilities and can deliver cargo proteins (up to 70 kDa) to the cytosol. To achieve tumor-specific cell targeting and cargo delivery through conditional activation of the cell-penetrating antibody in the tumor microenvironment, a single-chain Fc fragment (scFv) and a VL domain were isolated as masking units. Several in vitro assays demonstrated that fusing the masking protein with a cleavable linker to the cell penetration antibody results in the inactivation of antibody cell binding and internalization. Removal of the mask via MMP-9 protease cleavage, a protease that is frequently overexpressed in the tumor microenvironment (TME), led to complete regeneration of binding and cytosol-penetrating capabilities. Masked and conditionally activated cytosol-penetrating antibodies have the potential to serve as a modular platform for delivering protein cargoes addressing intracellular targets in tumor cells.

Funder

Federal Ministry of Education and Research

Deutsche Forschungsgemeinschaft

Publisher

MDPI AG

Reference88 articles.

1. Antibodies to combat viral infections: Development strategies and progress;Pantaleo;Nat. Rev. Drug Discov.,2022

2. Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., and Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci., 27.

3. A Brief Synopsis of Monoclonal Antibody for the Treatment of Various Groups of Diseases;Puthenpurail;World J. Pharm. Pharm. Sci.,2021

4. Targeting antibodies to the cytoplasm;Marschall;mAbs,2011

5. Targeting protein-protein interactions as an anticancer strategy;Ivanov;Trends Pharmacol. Sci.,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3